<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00328458</url>
  </required_header>
  <id_info>
    <org_study_id>03C.275</org_study_id>
    <secondary_id>2003-33</secondary_id>
    <nct_id>NCT00328458</nct_id>
  </id_info>
  <brief_title>EPO906 Plus Radiation Therapy for the Treatment of Cancer Patients</brief_title>
  <official_title>A Phase I, Open-label, Dose-escalation, Safety Study of the Combination of EPO906 and Radiation Therapy for the Treatment of Patients With Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Cancer Center at Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety of the drug EPO906 that could shrink
      tumors when used with radiation therapy in cancer patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  To determine the maximum tolerated dose (MTD) of EPO906 administered in combination with
           radiation therapy and establish a recommend phase II dose.

        -  To evaluate the safety and toxicity profile of EPO906 when administered concurrently
           with radiotherapy in three disease cohorts.

        -  To evaluate tumor response.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of EPO906</measure>
    <time_frame>Baseline to 7 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants that successful complete 7 weekly cycles of EPO906 concurrently with radiotherapy</measure>
    <time_frame>Baseline to 7 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Central Nervous System Neoplasms</condition>
  <condition>Head and Neck Neoplasms</condition>
  <arm_group>
    <arm_group_label>Cohort 1 Brain Tumors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The investigational drug - EPO906 will be administered as an intravenous infusion over five to ten minutes on weeks 1, 3 and 6, for the duration of radiation therapy up to a maximum of 7 weeks. Duration of therapy will be determined by disease cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 Head and Neck Tumors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The investigational drug - EPO906 will be administered as an intravenous infusion over five to ten minutes on weeks 1, 3 and 6, for the duration of radiation therapy up to a maximum of 7 weeks. Duration of therapy will be determined by disease cohort.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPO906 (epothilone B)</intervention_name>
    <arm_group_label>Cohort 1 Brain Tumors</arm_group_label>
    <arm_group_label>Cohort 2 Head and Neck Tumors</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Requires a minimum of 3 weeks of radiation therapy

          -  Solid tumors with advanced or recurrent disease for which there is no standard therapy
             or tumors have failed standard therapy

          -  World Health Organization (WHO) performance status equal to or less than 2

          -  Life expectancy equal to or greater than 3 months

        Exclusion Criteria:

          -  Any peripheral neuropathy

          -  Unresolved diarrhea greater than grade 1

          -  Patients who received any other investigational compound within the past 28 days

          -  Severe cardiac insufficiency

          -  Patients on Coumadin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam Dicker, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.KimmelCancerCenter.org</url>
    <description>Kimmel Cancer Center at Thomas Jefferson University, an NCI-Designated Cancer Center</description>
  </link>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>May 19, 2006</study_first_submitted>
  <study_first_submitted_qc>May 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2006</study_first_posted>
  <last_update_submitted>July 13, 2018</last_update_submitted>
  <last_update_submitted_qc>July 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CNS and head and neck cancers</keyword>
  <keyword>Histologically confirmed CNS malignancy head and neck</keyword>
  <keyword>there is on standard therapy or</keyword>
  <keyword>have failed standard therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epothilones</mesh_term>
    <mesh_term>Epothilone B</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

